In our current study, the prevention of the expression of hepatic TLR4, NF-κB, TGF-β by rifaximin highlights its suppressive effect on the TLR4/NF-κB signaling pathway in NASH rat model (Figure 5b–d). The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.